Welcome to our dedicated page for Hong Kong Pharma SEC filings (Ticker: HKPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a cross-border OTC distributor means wading through pages on import permits, logistics contracts, and drug-safety clauses. Hong Kong Pharma’s filings are especially dense because its Joint Cross Border and V-Alliance divisions must document every shipment route and regulatory approval. If you have ever asked, “Where can I find the Hong Kong Pharma quarterly earnings report 10-Q filing?” or “How do I decode a Hong Kong Pharma 8-K material events explained?”, you know the challenge.
Stock Titan solves that problem. Our AI reads each Hong Kong Pharma SEC filing the moment it hits EDGAR and produces plain-English summaries that highlight what matters: gross margin shifts between supply-chain services and procurement, new distribution licences disclosed in an 8-K, or insider confidence captured in Hong Kong Pharma insider trading Form 4 transactions. Need real-time alerts? Use our dashboard to spot Hong Kong Pharma Form 4 insider transactions real-time before the market reacts. Want depth? Drill into a Hong Kong Pharma annual report 10-K simplified, complete with risk-factor callouts and cash-flow tables already extracted.
Common investor tasks become faster: compare segment revenue with our Hong Kong Pharma earnings report filing analysis, monitor executive stock sales via Hong Kong Pharma executive stock transactions Form 4, or review pay packages in the Hong Kong Pharma proxy statement executive compensation section. Every document—10-K, 10-Q, 8-K, S-1, SC 13D—is updated in real time, and our expert context shows you how understanding Hong Kong Pharma SEC documents with AI can turn 200 pages into a five-minute read.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reports fiscal results and an extensive risk disclosure in its Form 20-F. The company completed a 1-for-10 share subdivision that increased issued shares to 11,000,000 (11,000 par units reported) and completed an IPO. Consolidated revenue lines shown in the filing include totals such as $20,313,818 and operating segments with revenue amounts like $7,511,591 and $6,217,798. The company recorded a net profit of $1,329,717 for one reported year and basic earnings per share of $0.180. Major shareholders and insider holdings are disclosed: the group of directors and officers hold 56.77% beneficially; Lap Sun Wong is identified as CEO and Chairman and retains controlling voting power. The filing lists extensive regulatory, geopolitical and operational risks, including concentration of customers and suppliers, IT and data governance risks, potential impact of PRC/Hong Kong regulation, possible Nasdaq listing pressures (past share price under $1 and delisting risk), and dependence on HK subsidiaries for cash distributions. The report also discloses material leases, licenses, and bank borrowings and notes key operating costs such as transportation and storage.
FAQ
What is the current stock price of Hong Kong Pharma (HKPD)?
What is the market cap of Hong Kong Pharma (HKPD)?
